Response Genetics to work with Roche on PCR analysis
This article was originally published in Clinica
Executive Summary
Roche Diagnostics is set to use Response Genetics’ PCR analysis technology to assess human epidermal growth factor type 2 (HER2) gene expression. Response granted Roche a non-exclusive license to the technology – financial terms of the collaboration were not disclosed. According to Los Angeles, California-based Response, the accurate measurement of HER2 gene expression can help professionals make treatment decisions for patients with breast cancer. Studies have shown that women with HER2-positive gene expression are three times more likely to have recurring cancer, even if the cancer is caught in the early stages. Roche and Response have combined previously in 2006, when the two firms worked alongside Eli Lilly to confirm biomarkers used to identify patients most likely to respond to certain cancer therapies.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals